566 related articles for article (PubMed ID: 25404094)
21. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
22. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
23. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
25. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
26. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Br J Haematol; 2010 Sep; 150(5):565-73. PubMed ID: 20629661
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
[TBL] [Abstract][Full Text] [Related]
31. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
32. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
33. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
34. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
35. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
36. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
37. UGT genotyping in belinostat dosing.
Goey AK; Figg WD
Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
[TBL] [Abstract][Full Text] [Related]
38. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
